Effects of Vibration Training in Interstitial Lung Diseases: A Randomized Controlled Trial.


Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
Historique:
received: 21 03 2020
accepted: 26 05 2020
pubmed: 20 8 2020
medline: 3 9 2021
entrez: 20 8 2020
Statut: ppublish

Résumé

Numerous studies have reported positive effects of exercise training in patients with interstitial lung disease (ILD) on physical capacity and quality of life. However, evidence is rare on the effects of specific forms of training and further pathophysiological mechanisms in these patients. In this multicenter study we aimed to explore the clinical effects of whole-body vibration training (WBVT) in patients with ILD on various outcome measures, including proinflammatory cytokines and myostatin. We randomly assigned 26 patients with different forms of multidisciplinary confirmed fibrotic ILDs either to the WBVT group (n = 11; 55% male, 61 ± 14 years old, forced vital capacity 83.2 ± 29.3% predicted, 6-min walking distance [6MWD] 478 ± 79 m) performing 3 months of a standardized training (3 times per week), or to a control training group (CTG, n = 15; 60% male, 63 ± 9 years old, FVC 74.6 ± 20.5% predicted, 6MWD 455 ± 85 m) performing sham WBV training. Training in the two groups was performed on a GalileoTM vibration plate (6-20 vs. 5 Hz). The functional assessments before and after the intervention period included pulmonary function, 6MWD test, chair rise test, ultrasonographic measurement of quadriceps muscle thickness (cross-sectional area), quality of life questionnaires, and serum samples. We observed a significant increase in 6MWD (∆Training = 30 m [12-67], p = 0.024) and a decrease of myostatin (∆Training = -465 pg/mL [-713 to -166], p = 0.008) in the WBVT group. In contrast, no significant differences were observed in the CTG. The present study demonstrates that WBVT is able to significantly increase 6MWD and decrease myostatin in patients with fibrotic ILDs. Therefore, WBVT seems to be a beneficial and feasible training modality in ILD patients. Clinical Trial Registry: German Clinical Trials Registry (DRKS00012930).

Sections du résumé

BACKGROUND BACKGROUND
Numerous studies have reported positive effects of exercise training in patients with interstitial lung disease (ILD) on physical capacity and quality of life. However, evidence is rare on the effects of specific forms of training and further pathophysiological mechanisms in these patients.
OBJECTIVES OBJECTIVE
In this multicenter study we aimed to explore the clinical effects of whole-body vibration training (WBVT) in patients with ILD on various outcome measures, including proinflammatory cytokines and myostatin.
METHODS METHODS
We randomly assigned 26 patients with different forms of multidisciplinary confirmed fibrotic ILDs either to the WBVT group (n = 11; 55% male, 61 ± 14 years old, forced vital capacity 83.2 ± 29.3% predicted, 6-min walking distance [6MWD] 478 ± 79 m) performing 3 months of a standardized training (3 times per week), or to a control training group (CTG, n = 15; 60% male, 63 ± 9 years old, FVC 74.6 ± 20.5% predicted, 6MWD 455 ± 85 m) performing sham WBV training. Training in the two groups was performed on a GalileoTM vibration plate (6-20 vs. 5 Hz). The functional assessments before and after the intervention period included pulmonary function, 6MWD test, chair rise test, ultrasonographic measurement of quadriceps muscle thickness (cross-sectional area), quality of life questionnaires, and serum samples.
RESULTS RESULTS
We observed a significant increase in 6MWD (∆Training = 30 m [12-67], p = 0.024) and a decrease of myostatin (∆Training = -465 pg/mL [-713 to -166], p = 0.008) in the WBVT group. In contrast, no significant differences were observed in the CTG.
CONCLUSIONS CONCLUSIONS
The present study demonstrates that WBVT is able to significantly increase 6MWD and decrease myostatin in patients with fibrotic ILDs. Therefore, WBVT seems to be a beneficial and feasible training modality in ILD patients. Clinical Trial Registry: German Clinical Trials Registry (DRKS00012930).

Identifiants

pubmed: 32814339
pii: 000508977
doi: 10.1159/000508977
doi:

Substances chimiques

Interleukin-6 0
Myostatin 0

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

658-666

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Andreas Rembert Koczulla (AR)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Teaching Hospital of Philipps-University of Marburg, Schoenau am Koenigssee, Germany.

Tobias Boeselt (T)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Janina Koelpin (J)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Fabian Kaufhold (F)

Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Germany and German Center for Lung Research, Heidelberg, Germany.

Martina Veith (M)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Christoph Nell (C)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Inga Jarosch (I)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany, ijarosch@schoen-klinik.de.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Teaching Hospital of Philipps-University of Marburg, Schoenau am Koenigssee, Germany, ijarosch@schoen-klinik.de.

Marc Spielmanns (M)

Pulmonology, Zuercher Reha Zentrum Wald, Wald, Switzerland.
Department of Pulmonary Medicine, Faculty of Health, University of Witten-Herdecke, Witten, Germany.

Peter Alter (P)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Christian Kähler (C)

Pneumology SKB, Private Clinic Kettenbruecke, Innsbruck, Austria.

Timm Greulich (T)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Claus F Vogelmeier (CF)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.

Rainer Glöckl (R)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Teaching Hospital of Philipps-University of Marburg, Schoenau am Koenigssee, Germany.

Tessa Schneeberger (T)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Teaching Hospital of Philipps-University of Marburg, Schoenau am Koenigssee, Germany.

Klaus Kenn (K)

Philipps-University of Marburg/Institute for Internal Medicine, Department of Pulmonology, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Teaching Hospital of Philipps-University of Marburg, Schoenau am Koenigssee, Germany.

Nicolas Carlos Kahn (NC)

Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Germany and German Center for Lung Research, Heidelberg, Germany.

Felix J F Herth (FJF)

Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Germany and German Center for Lung Research, Heidelberg, Germany.

Michael Kreuter (M)

Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Germany and German Center for Lung Research, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH